Christina Baik

Dr. Christina Baik


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 May 2017 in The Oncologist
Verified
Journal Article
Open access
PDF file
CBChristina Baik
Christina Baik
NMNathaniel J. Myall
Nathaniel J. Myall
HWHeather A. Wakelee
Heather A. Wakelee
Non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related deaths globally. However, the identification of oncogenic driver alterations involved in the initiation and maintenance of NSCLC, such as epidermal growth factor receptor mutations and anaplastic lymphoma kinase translocation, has led to the development of novel therapies that directly target mutant proteins and associated signaling pathways, resulting in improved clinical outcomes. As sequencing techniques have improved, the molecular heterogeneity of NSCLC has become apparent, leading to the identification of a number of potentially actionable oncogenic driver mutations. Of these, one of the most promising therapeutic targets is B-Raf proto-oncogene, serine/threonine kinase (BRAF). Mutations in BRAF, observed in 2%–4% of NSCLCs, typically lead to constitutive activation of the protein and, as a consequence, lead to activation of the mitogen-activated protein kinase signaling pathway. Direct inhibition of mutant BRAF and/or the downstream mitogen-activated protein kinase kinase (MEK) has led to prolonged survival in patients with BRAF-mutant metastatic melanoma. This comprehensive review will discuss the clinical characteristics and prognostic implications of BRAF-mutant NSCLC, the clinical development of BRAF and MEK inhibitors from melanoma to NSCLC, and practical considerations for clinicians involving BRAF mutation screening and the choice of targeted therapy.

31 August 2017 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
CBChristina Baik
Christina Baik
EREric H. Rubin
Eric H. Rubin
PFPatrick M. Forde
Patrick M. Forde
JMJanice M. Mehnert
Janice M. Mehnert
DCDeborah Collyar
Deborah Collyar
LCLaura Q.M. Chow
Laura Q.M. Chow
Recent advances in immuno-oncology and regulatory approvals have been rapid and paradigm shifting in many difficult-to-treat malignancies. Despite immune checkpoint inhibitor therapy becoming the standard of care across multiple tumor types, there are many unanswered questions that need to be addressed before this therapeutic modality can be fully harnessed. Areas of limitations include treatment of patients not sufficiently represented in clinical trials, uncertainty of the optimal treatment dosing and duration, and lack of understanding regarding long-term immune related toxicities and atypical tumor responses. Patients such as those with autoimmune disease, chronic viral infections, limited performance status, and brain metastases were often excluded from initial trials due to concerns of safety. However, limited data suggest that some of these patients can benefit from therapy with manageable toxicities; thus, future studies should incorporate these patients to clearly define safety and efficacy. There are still controversies regarding the optimal dosing strategy that can vary from weight-based to flat dosing, with undefined treatment duration. Further elucidation of the optimal dosing approach and evaluation of predictive biomarkers should be incorporated in the design of future trials. Finally, there are long-term immune-mediated toxicities, atypical tumor responses such as pseudoprogression and endpoints unique to immuno-oncology that are not adequately captured by traditional trial designs; thus, novel study designs are needed. In this article, we discuss in detail the above challenges and propose needed areas of research for exploration and incorporation in the next generation of immuno-oncology clinical trials. Clin Cancer Res; 23(17); 4992–5002. ©2017 AACR. See all articles in this CCR Focus section, “Clinical Trial Design Considerations in the Immuno-oncology Era.”

25 September 2012 in Cancers
Verified
Journal Article
Open access
PDF file
CBChristina Baik
Christina Baik
KEKeith Eaton
Keith Eaton
Lung cancer is the leading cause of cancer death in U.S. and represents a major public health burden. Epidemiologic data have suggested that lung cancer in women may possess different biological characteristics compared to men, as evidenced by a higher proportion of never-smokers among women with lung cancer. Emerging data indicate that female hormones such as estrogen and progesterone play a significant role in lung carcinogenesis. It has been reported that estrogen and progesterone receptors are expressed in lung cancer cell lines as well as in patient-derived tumors. Hormone related risk factors such as hormone replacement therapy have been implicated in lung carcinogenesis and several preclinical studies show activity of anti-estrogen therapy in lung cancer. In this review, we summarize the emerging evidence for the role of reproductive hormones in lung cancer and implications for lung cancer therapy.

1 January 2013 in Journal of Thoracic Oncology
Verified
Journal Article
Open access
PDF file
CBChristina Baik
Christina Baik
CPColin C. Pritchard
Colin C. Pritchard
KEKeith D. Eaton
Keith D. Eaton
LCLaura Q. Chow
Laura Q. Chow

20 May 2016 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
KEKeith Eaton
Keith Eaton
BGBernardo H. L. Goulart
Bernardo H. L. Goulart
RSRafael Santana-Davila
Rafael Santana-Davila
LCLaura Quan Man Chow
Laura Quan Man Chow
RWRebecca L. Wood
Rebecca L. Wood
RMRenato G. Martins
Renato G. Martins
6095 Background: Salivary gland cancers (SGC) are rare, biologically and histologically diverse malignancies with no standard of care therapy in the recurrent/metastatic setting. Eribulin is a microtubule inhibitor with established efficacy in previously treated breast cancer. The purpose of this study was to determine the anticancer activity of eribulin in advanced SGC. Methods: In a single center two-stage single arm phase II design, patients with progressive, recurrent and/or metastatic SCG of the head and neck or other sites, with documented disease progression within the past 6 months and not amenable to curative intent therapy were eligible. Any number of prior cytotoxic chemotherapies was allowed. Patients received eribulin 1.4 mg/m2 IV on Days 1 and 8 of a 21-day cycle until disease progression or unacceptable toxicities. Response was assessed by CT imaging every 6 weeks. The primary endpoint was overall response rate by RECIST 1.1. Secondary endpoints were duration of response (DOR), progression free survival (PFS), disease control rate (DCR), and grade > = 3 toxicities. Results: Between May 2012 and August 2015, 29 patients were enrolled. Median age was 63 (range 34-75); 20 (69%) were male. The most common histologies were adenoid cystic (n = 10) and adenocarcinoma (n = 5). Prior radiation was administered in 25 (86%). Number of prior cytotoxic therapies were: 0 (12, 41%), 1 (13, 45%), 3(3, 10%), 5 (1, 3%). Neutropenia was the most common toxicity (Grade 3 (9, 31%), Grade 4 (4, 14%)). Other grade 3 toxicities were: febrile neutropenia, increased QTc, fatigue and peripheral neuropathy in a single patient each. Median follow-up is 2 years, with 5 patients continuing on treatment. The median number of cycles administered was 4 (range 2-28). Response by RECIST criteria was observed in 3/29 (10%) with 2 PR and 1 CR , 20/29 (69%) patients demonstrated a decrement in tumor size at first assessment. Median PFS was 3 months, DCR was 26/29 (90%) and median DOR was 17.2 months. Conclusions: In this phase II trial of eribulin for advanced SGC, we observed response rates similar to those reported to other cytotoxic therapies and superior to those observed in trials of TKIs. Toxicities were similar to those observed in prior trials with eribulin. Clinical trial information: NCT01613768.

20 May 2016 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MKMargaret Winn Kendrick
Margaret Winn Kendrick
MRMary Weber Redman
Mary Weber Redman
KBKelsey K. Baker
Kelsey K. Baker
RMRenato G. Martins
Renato G. Martins
KEKeith Eaton
Keith Eaton
CRCristina P. Rodriguez
Cristina P. Rodriguez
6048 Background: Using PROs from our previously completed clinical trial (NCT00410826), we conducted an exploratory analysis to identify PRO associations with clinical factors and oncologic outcomes. Methods: From 12/2006 to 10/2011, 204 patients(pts) were randomized to cisplatin 100mg/m2 on radiation (XRT) days(d)1, 22, and 43 concurrent with 70Gy XRT (Arm A) or the same treatment with erlotinib 150mg daily starting XRT d-7 until XRT completion (Arm B). Using the validated University of Washington QOL form, PROs were measured on XRT d-7 (Arm B only), d0, d30, and d180. PRO associations with clinical factors and oncologic outcomes were explored using linear mixed, logistic and cox models, while adjusting for potential confounders. Results: One hundred eighty nine (93%) [Arm A (N = 97); Arm B (N = 92)] pts consented to PRO collection. PRO scores were available in Arm A: 55 (56%) pts at d0, 65 (67%) at d30, and 45 (46%) at d180 and Arm B: 82 (89%) pts at d-7, 58 (63%) at d0, 69 (75%) at d30, and 41 (44%) at d180. Demographic and tumor characteristics were well-balanced apart from more females in Arm A [20 (19%) vs 8 (8%); p = 0.03]. There were 7 (16%) black pts in Arm A and 13 (13%) in Arm B (p = 0.28). There was no change in mean PRO scores from d-7 on d0 (p = 0.83). Scores were significantly lower in both arms at d30 (estimated difference from baseline -13.21 (CI -18.32, -8.1), with no significant difference by Arm (p = 0.71). D180 remained lower than d-7 for Arm A (estimated difference from baseline -6.56 (CI -12.30, -0.82) p = 0.03), however were not significantly different from d-7 (baseline) in Arm B (p = 0.68). After adjusting for potential confounders on multivariable analysis, black race was an independent predictor for inferior PRO scores [OR -15.87; 95% CI (-21.11, -10.63); p < 0.0001] at all timepoints, complete response rates [OR 0.23; 95% CI (0.1, 0.53); p < 0.001] and overall survival [OR 3.94; 95% CI (1.89, 8.24); p < 0.001]. Conclusions: PRO worsened during chemoradiation, but returned to baseline in pts on Arm B. Black pts had inferior PRO and overall survival, meriting further investigation.